Levels of miR-142 in miR-142−/−BCR-ABL CML mice treated with CpG-M-miR-142 reached approximately 65% of the physiologic BM levels measured in miR-142+/+BCR-ABL mice, with ~60% reduction in the miR-142 target Cpt1a (Fig. 6c). The gene discussed is CPT1A; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.